A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Conditions

• Multiple Sclerosis
• Relapsing Multiple Sclerosis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• No Intervention — OTHER
  No Intervention

Study Details

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Key Dates

First listed

May 30, 2024

Start date

Jul 22, 2024

Status verified

Jun 2026

Primary completion

Apr 1, 2032

Completion

Apr 1, 2032

Study Design

Enrollment

2,000 participants (estimated)

Arms

• Arm: BRIUMVI® (Ublituximab-xiiy)
  Participants will receive BRIUMVI® (Ublituximab-xiiy) intravenous (IV) infusion for the treatment of RMS.

Primary Outcome Measure

Annualized Relapse Rate (ARR) [ Time Frame: Up to Week 96 ]

Central Contacts

• TG Therapeutics Clinical Support Team
  1-877-575-8489
  [email protected]

Locations (89)

Find similar trials in Birmingham, AL

Related Studies

• Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
  Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
• Serum Auto-Antibodies in Neurological Diseases
  Enrolling By Invitation · University of California, Davis · Sacramento, California
• Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• NARCOMS Registry: A Multiple Sclerosis Registry
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas